Statera Biopharma Signs Letter of Intent for Merger with Worksite Labs20230315120201
Statera Biopharma Announces Completion of Application Process to Uplist to the OTCQB® Venture Marketplace20230124144833
Statera Biopharma Announces BF Borgers CPA PC as Independent Registered Public Accounting Firm20220614113128
Statera Biopharma and Lay Sciences Inc. Announce Intent to Enter Strategic Partnership to License the Manufacturing Rights to Certain Lay Sciences IgY Products20220513113127
Statera Biopharma and Immune Therapeutics Inc. Announce Strategic Agreement for Rights to Low Dose Naltrexone20220427201142
Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-K Filing20220422212634
Statera Biopharma and Coeptis Therapeutics Announce Strategic Agreement for Rights to Entolimod20220413200641
Statera Biopharma, Inc. Files Form 12b-2520220331200648
Statera Biopharma, Inc. Files Form 12b-25
March 31, 2022
Statera Biopharma, Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on March 31, 202220220328113130
Statera Biopharma Announces Closing of $5.7 Million Underwritten Public Offering20220324212948